Please assess the completion status of the following clinical trial:

Trial Title: Dual bNAb Treatment in Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria for PK Step\*:~* On ART for at least 96 weeks~* Greater than or equal to 96 weeks and less than 5 years of age at enrollment~* HIV RNA less than 40 copies/mL for at least 24 weeks prior to entry~* Ability to remain in close study follow-up for at least 12 weeks~* Willingness to receive IV infusions of bNAbs~* Willingness to provide signed informed consent (by the parent/guardian)~  * \*It is anticipated that all children in PK Step will be from Early Infant Treatment (EIT) Study (NCT02369406); however, up to 4 HIV+ children outside the PK Study (age range 2-5 years) may participate in the PK Step if otherwise eligible and if EIT children are unavailable.~Inclusion Criteria for Entry into Step 1 (followed by participation in Steps 2-3):~* EIT Study participant (NCT02369406)~* On ART for at least 96 weeks~* Greater than or equal to 96 weeks and less than 7 years of age at enrollment~* HIV RNA less than 40 copies/mL for at least 24 weeks prior to entry~* Ability to remain in close study follow-up for at least 56 weeks~* Willingness to receive IV infusions of bNAbs~* Willingness to provide signed informed consent (by the parent/guardian)~Exclusion Criteria:~* Medical condition making survival for at least 32 weeks unlikely~* Active tuberculosis or malignancy~* Actively breastfeeding~* Previous receipt of VRC01/VRC01LS or 10-1074 (except during the PK Step)

- Gender: ALL
- Minimum Age: 96 Weeks
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Group PK-A: ART + VRC01LS (Type: EXPERIMENTAL): In the PK Step, participants will continue ART and receive VRC01LS at Weeks 0, 4, and 8 as a single intravenous (IV) dose (30 mg/kg load then 10 mg/kg maintenance).
- Group PK-B: ART + 10-1074 (Type: EXPERIMENTAL): In the PK Step, participants will continue ART and receive 10-1074 at Weeks 0, 4, and 8 as a single IV dose (30 mg/kg).
- Steps 1-3 Participants (ART + 10-1074 + VRC01LS) (Type: EXPERIMENTAL): In Step 1, eligible participants will continue to receive ART and will receive both 10-1074 and VRC01LS at Weeks 0, 4, and 8. Following a recommendation from the study team and Safety Monitoring Committee (SMC) to increase the maintenance dosing based on the PK Step, a VRC01LS loading dose of 30 mg/kg will be given at the start of Step 1, followed by 15 mg/kg dosing at each 4-weekly visit, and 10-1074 dosing will be at 30 mg/kg at each 4-weekly visit. In Step 2, participants with ongoing viral suppression throughout Step 1 will undergo withdrawal of ART and will continue maintenance 10-1074 (30 mg/kg) and VRC01LS (15 mg/kg) treatment for up to 24 weeks. In Step 3, both 10-1074 and VRC01LS will be discontinued and ART will be re-started.

Based on this trial design, predict the completion outcome and termination type (if applicable).